Patents by Inventor William Fenical
William Fenical has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10912764Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: GrantFiled: May 21, 2019Date of Patent: February 9, 2021Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
-
Publication number: 20190269651Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: May 21, 2019Publication date: September 5, 2019Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Patent number: 10314818Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: GrantFiled: July 20, 2017Date of Patent: June 11, 2019Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
-
Publication number: 20170319546Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: July 20, 2017Publication date: November 9, 2017Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Patent number: 9713607Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: GrantFiled: July 8, 2015Date of Patent: July 25, 2017Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
-
Patent number: 9481662Abstract: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.Type: GrantFiled: January 27, 2015Date of Patent: November 1, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: William Fenical, Paul R. Jensen, James J. La Clair, Lynnie Trzoss, Takashi Fukuda
-
Publication number: 20150313875Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: July 8, 2015Publication date: November 5, 2015Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Patent number: 9078881Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: GrantFiled: December 23, 2013Date of Patent: July 14, 2015Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
-
Publication number: 20150148314Abstract: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.Type: ApplicationFiled: January 27, 2015Publication date: May 28, 2015Inventors: William Fenical, Paul R. Jensen, James J. La Clair, Lynnie Trzoss, Takashi Fukuda
-
Publication number: 20140178354Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: December 23, 2013Publication date: June 26, 2014Applicant: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Patent number: 8637565Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: GrantFiled: May 22, 2012Date of Patent: January 28, 2014Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Publication number: 20120230972Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: May 22, 2012Publication date: September 13, 2012Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Patent number: 8222289Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: GrantFiled: December 15, 2009Date of Patent: July 17, 2012Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
-
Patent number: 8133902Abstract: A compound having the general the general structure I is provided: (Formula I), wherein Z is a substituent selected from a group consisting of S and O; X is a substituent selected from a group consisting of Cl, Br, I, OH and NH2; each of R1 and R2 is a substituent independently selected from a group consisting of H, a linear, cyclic or branched, substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl; and each of Y and Y1 is a substituent independently selected from a group consisting of H and C(O)—C6H4—Br.Type: GrantFiled: June 27, 2008Date of Patent: March 13, 2012Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, John MacMillan, Chambers C. Hughes, James J. LaClair
-
Publication number: 20110092534Abstract: A compound having the general the general structure I is provided: (Formula I), wherein Z is a substituent selected from a group consisting of S and O; X is a substituent selected from a group consisting of Cl, Br, I, OH and NH2; each of R1 and R2 is a substituent independently selected from a group consisting of H, a linear, cyclic or branched, substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl; and each of Y and Y1 is a substituent independently selected from a group consisting of H and C(O)—C6H4—Br.Type: ApplicationFiled: June 27, 2008Publication date: April 21, 2011Inventors: William Fenical, Paul Jensen, John Macmillan, Chambers C. Hughes, James J. Laclair
-
Patent number: 7928138Abstract: The invention is the discovery of an actinomycete genus, given the name Salinospora gen. nov., that displays an obligate requirement of seawater (Na+) for growth and unique 16S rRNA signature nucleotides. The invention is also the use of the genus for the production and discovery of active biomolecules such as pharmaceutical agents, agrichemicals, immunomodifiers, enzymes and enzyme inhibitors.Type: GrantFiled: December 28, 2007Date of Patent: April 19, 2011Assignee: Regents of the University of CaliforniaInventors: Robert H. R. Feling, William Fenical, Paul R. Jensen, Tracy J. Mincer
-
Patent number: 7879576Abstract: The invention is the discovery of an actinomycete genus, given the name Salinospora gen. nov., that displays an obligate requirement of seawater (Na+) for growth and unique 16S rRNA signature nucleotides. The invention is also the use of the genus for the production and discovery of active biomolecules such as pharmaceutical agents, agrichemicals, immunomodifiers, enzymes and enzyme inhibitors.Type: GrantFiled: August 20, 2007Date of Patent: February 1, 2011Assignee: Regents of the University of CaliforniaInventors: William Fenical, Paul R. Jensen, Tracy J. Mincer
-
Publication number: 20100144826Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: December 15, 2009Publication date: June 10, 2010Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
-
Patent number: 7635712Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: GrantFiled: February 12, 2007Date of Patent: December 22, 2009Assignee: The Regents of the University of CaliforniaInventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
-
Publication number: 20090197937Abstract: The invention is the discovery of an actinomycete genus, given the name Salinospora gen. nov., that displays an obligate requirement of seawater (Na+) for growth and unique 16S rRNA signature nucleotides. The invention is also the use of the genus for the production and discovery of active biomolecules such as pharmaceutical agents, agrichemicals, immunomodifiers, enzymes and enzyme inhibitors.Type: ApplicationFiled: December 28, 2007Publication date: August 6, 2009Inventors: William Fenical, Paul R. Jensen, Tracy J. Mincer, Robert H. R. Feling